Humanigen Announces Participation and Presentation at H.C. Wainwright Global Investment Conference

SHORT HILLS, N.J.--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ announced that Cameron Durrant, Chairman & CEO, will give a corporate presentation at 11:00am EDT today at the H.C. Wainwright Global Investment Conference taking place in Miami, FL, May 23-26, 2022. In his presentation Dr. Durrant will provide an update on progress towards release of topline data for ACTIV-5/BET-B and the company’s plans and goals for the remainder of 2022.

“There have been 1 million hospitalizations and 173,738 deaths with COVID-19 to date this year, placing the U.S. on course to record more than 2 million hospitalizations for the second year in a row and underscoring the need for additional therapeutics for those who become hospitalized with COVID-19,” said Dr. Durrant.

A livestream will be available and a webcast link to a recording of the event will be posted to the “Events and Presentations” section of Humanigen’s investor relations website for 90 days after the event at ir.humanigen.com.

Webcast: https://journey.ct.events/view/8e10da2e-d387-4ab0-97c2-fd6aec9fd7ef

About Humanigen

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’. Lenzilumab is a first-in class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). Results from preclinical models indicate GM-CSF is an upstream regulator of many inflammatory cytokines and chemokines involved in the cytokine storm. Early in the COVID-19 pandemic, investigation showed high levels of GM-CSF secreting T cells were associated with disease severity and intensive care unit admission. Humanigen’s Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent consequences of a full-blown cytokine storm in hospitalized patients with COVID-19. Humanigen is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 and CD19-targeted CAR-T cell therapies and is also exploring the effectiveness of lenzilumab in other inflammatory conditions such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation, eosinophilic asthma, and rheumatoid arthritis. For more information, visit www.humanigen.com and follow Humanigen on LinkedIn, Twitter, and Facebook.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward- looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our plans relating to lenzilumab.

Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections of our latest annual and quarterly reports and other filings with the SEC.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. We undertake no obligation to revise or update any forward-looking statements made in this presentation to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unanticipated events, to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, in each case, except as required by law.

References

1. Centers for Disease Control and Prevention. (2022, May 23). CDC Covid Data tracker. Centers for Disease Control and Prevention. Retrieved May 23, 2022, from https://covid.cdc.gov/covid-data-tracker/#new-hospital-admissions
2. Centers for Disease Control and Prevention. (2022, May 23). CDC Covid Data tracker. Centers for Disease Control and Prevention. Retrieved May 23, 2022, from https://covid.cdc.gov/covid-data-tracker/#trends_totaldeaths

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005429/en/

Humanigen Investor Relations

Ken Trbovich

Humanigen

trbo@humanigen.com

650-410-3206

Source: Humanigen, Inc.